Nektar End Period Cash Flow from 2010 to 2025
| NKTR Stock | USD 0.85 0.03 2.89% |
End Period Cash Flow | First Reported 1994-03-31 | Previous Quarter 13.9 M | Current Value 30.1 M | Quarterly Volatility 100.3 M |
Check Nektar Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nektar Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 17.6 M, Interest Expense of 24.1 M or Total Revenue of 160.5 M, as well as many indicators such as Price To Sales Ratio of 1.85, Dividend Yield of 0.0 or PTB Ratio of 2.99. Nektar financial statements analysis is a perfect complement when working with Nektar Therapeutics Valuation or Volatility modules.
Nektar | End Period Cash Flow |
Latest Nektar Therapeutics' End Period Cash Flow Growth Pattern
Below is the plot of the End Period Cash Flow of Nektar Therapeutics over the last few years. It is Nektar Therapeutics' End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Nektar Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| End Period Cash Flow | 10 Years Trend |
|
End Period Cash Flow |
| Timeline |
Nektar End Period Cash Flow Regression Statistics
| Arithmetic Mean | 61,042,404 | |
| Geometric Mean | 39,001,446 | |
| Coefficient Of Variation | 97.58 | |
| Mean Deviation | 43,008,306 | |
| Median | 44,252,000 | |
| Standard Deviation | 59,562,801 | |
| Sample Variance | 3547.7T | |
| Range | 194.2M | |
| R-Value | 0.35 | |
| Mean Square Error | 3347.5T | |
| R-Squared | 0.12 | |
| Significance | 0.19 | |
| Slope | 4,322,110 | |
| Total Sum of Squares | 53215.9T |
Nektar End Period Cash Flow History
About Nektar Therapeutics Financial Statements
Nektar Therapeutics shareholders use historical fundamental indicators, such as End Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Nektar Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Nektar Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Nektar Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| End Period Cash Flow | 44.3 M | 70.8 M |
Pair Trading with Nektar Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nektar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nektar Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Nektar Stock
| 0.53 | VALN | Valneva SE ADR | PairCorr |
| 0.53 | SRZNW | Surrozen Warrant | PairCorr |
| 0.47 | VIGL | Vigil Neuroscience | PairCorr |
| 0.44 | DMAC | DiaMedica Therapeutics | PairCorr |
| 0.36 | VERV | Verve Therapeutics | PairCorr |
The ability to find closely correlated positions to Nektar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nektar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nektar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nektar Therapeutics to buy it.
The correlation of Nektar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nektar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nektar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nektar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Nektar Stock Analysis
When running Nektar Therapeutics' price analysis, check to measure Nektar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nektar Therapeutics is operating at the current time. Most of Nektar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nektar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nektar Therapeutics' price. Additionally, you may evaluate how the addition of Nektar Therapeutics to your portfolios can decrease your overall portfolio volatility.